Program
polyethylene glycol 3350
Also written as “NER1006”, “polyethyleneglycol3350” and “HalfLytely”.
Its studies are mostly in Constipation · Colonic Neoplasms · Opioid-Induced Constipation · Colorectal Neoplasms · Enterocolitis, Pseudomembranous, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sebela Pharmaceuticals | 100 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Bayer | 30 open or running | phase 4since Oct 9, 2008 | Oct 9, 2008 | none ahead |
| Ascension Health | 10 open or running | phase 4since Jun 21, 2012 | Jun 21, 2012 | none ahead |
| Taejoon Pharmaceutical | 10 open or running | phase 3since Apr 21, 2023 | Apr 21, 2023 | none ahead |
Also a collaborator on its studies: Parexel, Quotient Sciences and Pierrel Research Europe.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2005First studies: 6 phase 4 studiesNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT00153153, NCT00153140, NCT00153127 and 3 more
- Sep 9, 20052 phase 3 studies in ColonoscopySebela Pharmaceuticals · NCT00164164, NCT00164151
- Apr 27, 2006Phase 4 study in ConstipationSebela Pharmaceuticals · NCT00319670 · 25 enrolled · United States
- Dec 20, 2007Phase 4 study in ConstipationSebela Pharmaceuticals · NCT00583609 · 20 enrolled · United States
- Oct 9, 2008Bayer’s first study: phase 4 study in ConstipationNew to BayerBayer · NCT00770432 · 203 enrolled
- Sep 29, 2010Phase 2 study in ConstipationBayer · NCT01212445 · 154 enrolled · Ireland
- Jun 21, 2012Ascension Health’s first study: phase 4 study in Enterocolitis, PseudomembranousNew to Ascension HealthAscension Health · NCT01630096 · 200 enrolled · United States
- Nov 12, 2014Phase 3 study in ConstipationBayer · NCT02292459
- Apr 21, 2023Taejoon Pharmaceutical’s first study: phase 3 study in Bowel PreparationNew to Taejoon PharmaceuticalTaejoon Pharmaceutical · NCT05870553 · 137 enrolled · Korea, Republic of
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05870553Bowel Preparation · Korea, Republic of | 3 | Completed | Taejoon Pharmaceutical | May 12, 2023 | 137 |
| NCT02292459Constipation | 3 | Withdrawn | Bayer | Dec 2015 | 0 |
| NCT01630096Enterocolitis, Pseudomembranous · United States | 4 | UNKNOWN | Ascension Health | Jun 2014 | 200 |
| NCT01212445Constipation · Ireland | 2 | Completed | Bayer | Nov 2011 | 154 |
| NCT00770432Constipation | 4 | Completed | Bayer | Jan 2008 | 203 |
| NCT00583609Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Jul 2008 | 20 |
| NCT00319670Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | May 2006 | 25 |
| NCT00164177Colonoscopy · United States | 4 | Completed | Sebela Pharmaceuticals | Dec 2004 | 20 |
| NCT00164164Colonoscopy · United States | 3 | Completed | Sebela Pharmaceuticals | Jun 2000 | 200 |
| NCT00164151Colonoscopy · United States | 3 | Completed | Sebela Pharmaceuticals | May 2002 | 60 |
| NCT00164125Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Nov 2004 | 300 |
| NCT00153153Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Dec 2004 | 300 |
| NCT00153140Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Oct 2004 | 239 |
| NCT00153127Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Sep 2004 | 100 |
| NCT00153114Constipation · United States | 4 | Completed | Sebela Pharmaceuticals | Sep 2004 | 100 |
How it is read
Names in the registry
- “NER1006”, 9 entries
- “polyethyleneglycol3350”, 5 entries
- “HalfLytely”, 3 entries
- “PEG 3350 plus electrolytes”, 2 entries
- “PLENVU®”, 1 entry
Conditions, from the studies’ own filings
- Constipation, 13 studies
- Colonic Neoplasms, 2 studies
- Opioid-Induced Constipation, 1 study
- Colorectal Neoplasms, 1 study
- Enterocolitis, Pseudomembranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.